Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-human chorionic gonadotropin
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
Beta-human chorionic gonadotropin (beta-hCG) is the beta subunit of human chorionic gonadotropin (hCG), a hormone primarily produced by the placenta during pregnancy. Its presence and levels in blood or urine are crucial for diagnosing and monitoring various pregnancy-related conditions, such as ectopic pregnancy, molar pregnancy, and fetal growth restriction. It also serves as a tumor marker for certain cancers, including testicular cancer and gestational trophoblastic disease.
- Brand names
- NovarelOvidrelPregnylChorexProfasi
- Other names
- beta-HCGβ-hCG
02
Targets
LHCGR (Luteinizing hormone/choriogonadotropin receptor)TSHR (Thyroid-stimulating hormone receptor)
Beyond the preview
Go deeper on beta-human chorionic gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-human chorionic gonadotropin.